Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007Eric Lim, Peter Goldstraw, Andrew G Nicholson, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignanciesFrank C Detterbeck, Hisao Asamura, John Crowley, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007Eric Lim, Peter Goldstraw, Andrew G Nicholson, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
The New England Journal of Medicine|March 10, 2006
Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie, Guido Tricot, Elias Anaissie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignanciesFrank C Detterbeck, Hisao Asamura, John Crowley, et al.
Pageof 18